Physician Data Query

Last uploaded: January 31, 2024
Preferred Name

palbociclib

Synonyms

Ibrance

Definitions

An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C49176" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49176" NCI Thesaurus)

ID

http://purl.bioontology.org/ontology/PDQ/CDR0000454586

altLabel

Ibrance

PD-0332991

PD-332991

6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one

CAS Registry

571190-30-2

cui

C3853822

C1568660

C3883373

DATE FIRST PUBLISHED

2005-11-04

Date last modified

2015-03-20

definition

An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C49176" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49176" NCI Thesaurus)

LT

TRD

NCI ID

C49176

notation

CDR0000454586

ORIG STY

Drug/agent

prefLabel

palbociclib

tui

T109

T121

Delete Subject Author Type Created
No notes to display
Create mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/SNOMEDCT/715958001 SNOMEDCT CUI
http://purl.bioontology.org/ontology/MESH/C500026 MESH CUI
http://purl.bioontology.org/ontology/RXNORM/1601381 RXNORM CUI
http://purl.bioontology.org/ontology/VANDF/4034136 VANDF CUI
http://purl.bioontology.org/ontology/RXNORM/1601374 RXNORM CUI
http://purl.bioontology.org/ontology/SCTSPA/715958001 SCTSPA CUI
http://purl.bioontology.org/ontology/NDDF/015881 NDDF CUI
http://purl.bioontology.org/ontology/SNOMEDCT/763549001 SNOMEDCT CUI
http://purl.bioontology.org/ontology/ATC/L01EF01 ATC CUI
http://purl.bioontology.org/ontology/NDFRT/N0000191426 NDFRT CUI
http://purl.bioontology.org/ontology/SCTSPA/763549001 SCTSPA CUI
http://purl.bioontology.org/ontology/MESH/C500026 MESH CUI
http://purl.bioontology.org/ontology/MESH/C500026 MESH CUI
http://purl.obolibrary.org/obo/CHEBI_85993 PDRO LOOM
http://purl.obolibrary.org/obo/CHEBI_85993 FIDEO LOOM
http://purl.obolibrary.org/obo/CHEBI_85993 BERO LOOM
http://purl.obolibrary.org/obo/CHEBI_85993 DRON LOOM
http://purl.obolibrary.org/obo/CHEBI_85993 CHEBI LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/715958001 SNOMEDCT LOOM
http://purl.jp/bio/4/id/201506019724062439 IOBC LOOM
http://purl.bioontology.org/ontology/VANDF/4034136 VANDF LOOM
http://purl.bioontology.org/ontology/RXNORM/1601374 RXNORM LOOM
https://go.drugbank.com/drugs/DB09073 MDM LOOM
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C49176 NCIT LOOM
http://purl.bioontology.org/ontology/ATC/L01EF01 ATC LOOM
http://stirdf.jst.go.jp/id/201207074299826898 IOBC LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000191426 NDFRT LOOM
http://www.phoc.org.cn/pmo/class/PMO_00026241 PMAPP-PMO LOOM
http://purl.obolibrary.org/obo/NCIT_C49176 BERO LOOM
http://purl.bioontology.org/ontology/MESH/C500026 MESH LOOM